文献速递冠心病外科

强化与中等强度他汀治疗对冠状动脉旁路移植术后早期移植物闭塞的影响:抑制静脉移植物事件的积极胆固醇治疗随机临床试验

Intensive versus moderate statin therapy and early graft occlusion after coronary bypass surgery: The Aggressive Cholesterol Therapy to Inhibit Vein Graft Events randomized clinical trial.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-07-21

该多中心、双盲、先导性随机试验将173例接受冠状动脉旁路移植术并使用大隐静脉桥的患者随机分为阿托伐他汀每日10 mg组或80 mg组,治疗1年。1年时静脉桥闭塞率在10 mg组为12.9%、80 mg组为11.4%,两组无显著差异(P=0.85);80 mg组低密度脂蛋白胆固醇水平显著更低(P<0.00001),但静脉桥病变(闭塞或狭窄)有减少趋势(29.2% vs 19.2%,P=0.18),主要不良心血管事件无显著差异(P=0.27)。

要点

  • 在冠状动脉旁路移植术后1年,阿托伐他汀80 mg与10 mg相比未显著降低大隐静脉桥闭塞率(12.9% vs 11.4%,P=0.85)。
  • 80 mg阿托伐他汀组低密度脂蛋白胆固醇水平显著低于10 mg组(P<0.00001)。
  • 80 mg组静脉桥病变(闭塞或狭窄)有减少趋势(29.2% vs 19.2%,P=0.18),主要不良心血管事件无显著差异(P=0.27)。

核心结论

  • 在此先导性试验中,与阿托伐他汀10 mg相比,阿托伐他汀80 mg未显著降低冠状动脉旁路移植术后1年的大隐静脉桥闭塞率。

研究设计与样本

  • 多中心、双盲、先导性随机临床试验,纳入173例接受冠状动脉旁路移植术并使用大隐静脉桥的患者,随机接受阿托伐他汀每日10 mg或80 mg治疗1年。

主要发现

  • 1年时静脉桥闭塞率在阿托伐他汀10 mg组为12.9%,80 mg组为11.4%,两组无显著差异(P=0.85)。
  • 静脉桥狭窄发生率两组无显著差异(P=0.54)。
  • 静脉桥病变(闭塞或狭窄)在阿托伐他汀10 mg组为29.2%,80 mg组为19.2%,两组差异未达统计学显著(P=0.18)。
  • 1年无主要不良心血管事件生存率两组相似(P=0.27)。
  • 试验入组期间,随机接受阿托伐他汀80 mg的患者达到显著更低的低密度脂蛋白胆固醇水平(P<0.00001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Statins prevent saphenous vein graft (SVG) disease and improve outcomes after coronary artery bypass graft surgery. However, the optimal postoperative statin dose remains unclear. The Aggressive Cholesterol Therapy to Inhibit Vein Graft Events trial was undertaken to evaluate whether early postoperative high-dose statin therapy reduces SVG occlusion compared with conventional moderate-dose therapy. METHODS: In this pilot, multicenter, double-blind randomized trial, 173 patients who had coronary artery bypass graft surgery with SVG were randomized to receive 10 mg or 80 mg atorvastatin daily for 1 year. The primary outcome was SVG occlusion at 1 year. Secondary outcomes were SVG stenosis and major adverse cardiovascular events. RESULTS: During trial enrollment, patients randomized to 80 mg atorvastatin achieved significantly lower low-density lipoprotein cholesterol levels (P < .00001). One-year graft assessment was performed in 145 patients (83.8%). The primary outcome, SVG occlusion at 1 year, did not significantly differ between the 2 groups (12.9% vs 11.4% for 10 mg atorvastatin vs 80 mg atorvastatin; P = .85). The incidence of vein graft stenosis also did not significantly differ between the groups (P = .54). However, there was a trend toward fewer patients developing vein graft disease (either occlusion or stenosis) in the 80 mg atorvastatin group (29.2% vs 19.2%, 10 mg atorvastatin vs 80 mg atorvastatin; P = .18). Freedom from major adverse cardiovascular events at 1 year was similar between the groups (P = .27). CONCLUSIONS: Compared with 10 mg atorvastatin, 80 mg atorvastatin did not significantly reduce vein graft occlusion 1 year after coronary artery bypass graft surgery in this pilot trial.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Kulik A, Abreu AM, Boronat V, et al. Intensive versus moderate statin therapy and early graft occlusion after coronary bypass surgery: The Aggressive Cholesterol Therapy to Inhibit Vein Graft Events randomized clinical trial. J Thorac Cardiovasc Surg. 2018. PMID: 30122341. doi:10.1016/j.jtcvs.2018.05.123

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。